Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.815 USD | -0.27% | -3.97% | -87.67% |
14/05 | Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating | MT |
09/05 | Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.67% | 124M | |
+0.10% | 91.42B | |
+3.16% | 41.08B | |
-10.92% | 34.26B | |
+53.99% | 25.27B | |
-9.92% | 12.81B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-6.90% | 8.22B |
- Stock Market
- Equities
- AMLX Stock
- News Amylyx Pharmaceuticals, Inc.
- Goldman Sachs Upgrades Amylyx Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $49 From $45